Smuckers makes peanut butter? I've only seen their jelly.
Follow along with the video below to see how to install our site as a web app on your home screen.
Note: This feature may not be available in some browsers.
Abbott Labs Recalls Powder Baby Formula
Millions Of Canisters May Be Contaminated With Insects
MATTHEW PERRONE, AP Health Writer
UPDATED: 9:59 pm CDT September 22, 2010
WASHINGTON -- Drugmaker Abbott Laboratories said Wednesday it is recalling millions of containers of its best-selling Similac infant formula that may be contaminated with insect parts.
The voluntary action affects up to 5 million Similac-brand powder formulas sold in the U.S., Puerto Rico, Guam and some Caribbean countries. The company said the products may contain a small beetle or larvae, which could cause stomach ache and digestion problems.
The recall does not affect any liquid formulas or other Abbott-brand products.
A company spokeswoman said Abbott uncovered the insects last week in one section of a manufacturing plant in Sturgis, Michigan.
"We immediately shut down that one area and began an investigation," said Abbott's Melissa Brotz. "We're in the process of resolving it now." Abbott manufactures Similac at several U.S. sites.
Brotz said the company has been consulting with the Food and Drug Administration, which determined there was no "immediate health risk" from the contamination.
Consumers can enter the lot number on their containers online to determine if they are subject to the recall. The products should be returned to Abbott for a full refund.
"Delivering anything less than the highest quality infant formula is unacceptable to us," said Brotz. "We will do whatever is necessary to maintain the trust of parents in the coming weeks."
The affected products were sold in plastic containers and various can sizes, including 8-ounce (227-gram), 12.4-ounce (352-gram) and 12.9-ounce (366-gram).
Similac is the best-selling infant formula in the U.S. Abbott's nutritional products - which include adult brands like Ensure - had sales of $5.3 billion last year.
Abbott expects to lose $100 million in connection with the recall. However, the North Chicago, Illinois, company confirmed its third-quarter earnings guidance between $1.03 and $1.05 per share.
Shares of Abbott Laboratories fell 16 cents to $51.99.
Some of the hotels I have worked at usually have Smuckers single serving cups of peanut butter on the breakfast bar. But this recall only affects the jars.Smuckers makes peanut butter? I've only seen their jelly.
Reuters) - The U.S. unit of Novartis AG on Sunday issued a nationwide recall of certain bottled versions of Excedrin and Bufferin, and two other products, because they may contain stray, broken or chipped tablets from other Novartis products.
Novartis Consumer Health said the recall, which also applies to bottled versions of NoDoz and Gas-X Prevention, is a precautionary measure.
Novartis said mixing of different products in the same bottle could result in taking an incorrect product or receiving a higher or lower strength than intended or receiving an unintended ingredient, which could potentially result in overdose or an allergic reaction.
Novartis said it has voluntarily suspended operations and shipments from its Lincoln, Nebraska, facility to rectify the problems at the site. Novartis said its Consumer Health unit will take a one-time charge currently estimated at $120 million in the fourth quarter relating to the recalls and improvements at the facility.
Novartis said the recall is being conducted with the knowledge of the U.S. Food and Drug Administration.
The recall is for bottled packages of Excedrin and NoDoz with expiration dates of December 20, 2014, or earlier, and for Bufferin and Gas-X Prevention products with expiration dates of December 20, 2013, or earlier.
Novartis said there had not been any adverse events reported and that the U.S. Food and Drug Administration (FDA) was aware of the recall.
The products are being recalled due to an internal product review and complaints that identified issues such as broken gelcaps, chipped tablets and inconsistent bottle packaging line clearance practices, where a potential for a tablet mix up could not be ruled out.
The company said it has notified its distributors and retailers. Consumers can find more information on the website ww.novartis-otc.com/otc/index.html.
Novartis Issues Recall on Excedrin, Buffrin
Reuters) - The U.S. unit of Novartis AG on Sunday issued a nationwide recall of certain bottled versions of Excedrin and Bufferin, and two other products, because they may contain stray, broken or chipped tablets from other Novartis products.
Novartis Consumer Health said the recall, which also applies to bottled versions of NoDoz and Gas-X Prevention, is a precautionary measure.
Novartis said mixing of different products in the same bottle could result in taking an incorrect product or receiving a higher or lower strength than intended or receiving an unintended ingredient, which could potentially result in overdose or an allergic reaction.
Novartis said it has voluntarily suspended operations and shipments from its Lincoln, Nebraska, facility to rectify the problems at the site. Novartis said its Consumer Health unit will take a one-time charge currently estimated at $120 million in the fourth quarter relating to the recalls and improvements at the facility.
Novartis said the recall is being conducted with the knowledge of the U.S. Food and Drug Administration.
The recall is for bottled packages of Excedrin and NoDoz with expiration dates of December 20, 2014, or earlier, and for Bufferin and Gas-X Prevention products with expiration dates of December 20, 2013, or earlier.
Novartis said there had not been any adverse events reported and that the U.S. Food and Drug Administration (FDA) was aware of the recall.
The products are being recalled due to an internal product review and complaints that identified issues such as broken gelcaps, chipped tablets and inconsistent bottle packaging line clearance practices, where a potential for a tablet mix up could not be ruled out.
The company said it has notified its distributors and retailers. Consumers can find more information on the website ww.novartis-otc.com/otc/index.html.
Susan